Home biosimilars

Keyword: biosimilars

48 results found

As the coronavirus pandemic continues, fewer Canadian benefits plan members are making drug claims, according to Telus Health’s annual drug trends report. The report, based on the drug claims activity of more than 10 million plan members in 2021, found just 56 per cent made a claim in 2021, reflecting a decreased frequency of in-person […]

  • By: Staff
  • June 23, 2022 June 22, 2022
  • 09:00
Copyright_Wavebreak Media Ltd_123RF

Changes to Quebec’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans, says one expert. On April 13, 2022, the Régie de l’assurance maladie du Québec will delist certain biologic drugs from its formulary, requiring patients covered by the plan to switch to a biosimilar […]

This month marks the second anniversary of the beginning of the coronavirus pandemic, a 24-month span that has had profound effects on the health of benefits plan members and the status and structure of their plans. For drug plans in particular, several trends have come to light — or have accelerated — during the course […]

Copyright_Aleksandr Kalugin_123RF

In 2020, Canada Life Assurance Co. saw a decrease in the number of benefits plan members making a drug claim, though the costs of those claims were higher, according to Barb Martinez, the insurer’s national practice leader in drug solutions, speaking during a session at Benefits Canada‘s Face to Face in Drug Plan Management Forum […]

Copyright_rmarmion_123RF

As inflation hits a record high in Canada, employers are helping workers weather the storm through various benefits and compensation offerings, according to several experts. In October, the Canadian inflation rate increased year over year by a record 4.7 per cent, the largest increase since February 2003, according to Statistics Canada. The Bank of Canada […]

Prescription drug costs for public drug plans rose to $12.5 billion in 2019/20, a 3.7 per cent rise in spending since 2017/18, driven primarily by increases in the use of higher-cost drugs, according to a report by the Patented Medicine Prices Review Board. The report, which reviewed data from the National Prescription Drug Utilization Information […]

  • By: Staff
  • November 12, 2021 November 12, 2021
  • 09:00
Copyright_tomertu_123RF

More than 19 months into the coronavirus pandemic, employers are focusing on enhanced mental-health offerings and streamlined communications for their benefits and pension plans. During a virtual roundtable on Oct. 14, the 2021 Workplace Benefits Awards finalists discussed the changes brought about by the pandemic and how they’ve adapted their benefits and pensions offerings, while looking […]

While one side highlights how plan sponsors can contribute to biosimilar sustainability, the other touts the benefits to patients and the health-care system. Durhane Wong-Rieger, president and chief executive officer, Institute for Optimizing Health Outcomes The Institute for Optimizing Health Outcomes recently published a scorecard rating the biosimilar policy frameworks of European countries across seven […]

Copyright_Aleksandr Kalugin_123RF

Canadians’ health priorities are shifting as the coronavirus pandemic drags on, as claims for medications to treat mental-health conditions continued to rise in 2020, along with claims for specialty drugs designed to treat rarer, yet increasingly chronic diseases, according to Telus Health’s annual drug trends report. There were noticeable shifts in the utilization of mental-health […]

The growing use of specialty medications among plan members continued to drive the increase in plan sponsors’ drug plan costs last year, well eclipsing the increase in traditional drug spending, according to Telus Health. Canadian plan sponsors’ drug spending on insured plan members between the ages of 25 and 64 increased 3.6 per cent in […]